winner, winner

Houston 3D printing company selected inaugural competition

This innovative Houston company has the national spotlight this week. Courtesy of re:3D

A Houston company has been announced among the winners of an inaugural seed fund expo competition.

Twelve startups were announced across four categories in the U.S. Small Business Administration's inaugural America’s Seed Fund Startup Expo 2022, which is taking place virtually Wednesday, May 25, from 11:30 am to 3:30 pm. Each of the 12 companies have developed innovative technologies with the help of SBIR grants.

“Every day, in communities across America, entrepreneurs are solving our nation’s most pressing challenges from climate change to feeding and healing the world. The SBA is committed to helping ensure that those ideas receive the necessary support from federal programs and innovation ecosystems so that they can commercialize and grow into resilient businesses,” says Administrator Isabella Casillas Guzman in a news release.

“With the launch of America's Seed Fund Expo, we will showcase exceptional entrepreneurs who have leveraged federal research and development funding through the SBIR Program in key industries and connect them to resources to advance their game-changing innovations right here in America,” she continues.

Houston-based Re:3D is among the companies selected to present at the expo. The complete list of participating companies is as follows:

  • AgTech and Food Security
    • General Probiotics (Saint Paul, MN)
    • Nucleic Sensing Systems (Saint Paul, MN)
    • Shellfish Solutions d/b/a Blue Trace (Castine, ME)
  • Climate and Energy
    • Amorphic Tech (Allentown, PA)
    • FGC Plasma Solutions (Middleton, MA)
    • Hydroplane (Lancaster, CA)
  • National Security and Defense
    • BadVR (Pacoima, CA)
    • Enduralock (Lenexa, KS)
    • PSYONIC (Champaign, IL)
  • Supply Chain Resiliency
    • Chromatic 3D Materials (Golden Valley, MN)
    • Delta Development Team (Tucson, AZ)
    • Re:3D (Houston, TX)

“The giants of future industries so often start as small business startups with big ideas," says Bailey DeVries, associate administrator of the office of investment and innovation, in the news release. "We know the public and private sectors must work together to nurture these small businesses with big ideas over many years so they may sustain and grow. America’s Seed Fund Startup Expo will lift up big ideas and provide a platform for our national innovation community to support the businesses of tomorrow."

The event is free to attend virtually, and anyone can register online at https://bit.ly/SeedFundExpoRSVP. The America’s Seed Fund is among the Small Business Innovation Research and Small Business Technology Transfer programs and is collaborates with 11 federal agencies, that collectively support more than $4 billion a year in federal research and development funding.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted